CLGN - コルプラント・ホ―ルディングス (CollPlant Holdings Ltd.) コルプラント・ホ―ルディングス

 CLGNのチャート


 CLGNの企業情報

symbol CLGN
会社名 CollPlant Holdings Ltd (コルプラント・ホ―ルディングス)
分野(sector) Health Care   ヘルスケア
産業(industry) Industrial Specialties  
業種    医療関連(Health Care)
概要 事業概要 --   コルプラント・ホ―ルディングスはイスラエルの再生医薬品メ―カ―。組織や器官の3Dバイオプリンティングに注力し、人体由来・天然性の材料を用いるオ―ソバイオロジクスや先進創傷ケア市場向けの組織修復用医薬品の開発・商業化に従事する。同社製品は遺伝子工学技術における独自の組み換え体ヒトコラ―ゲンに基づく。本社所在地はネスジオナ。   
本社所在地 3 Sapir Street Weizmann Science Park Ness Ziona 74140 ISR
代表者氏名
代表者役職名
電話番号
設立年月日 2004年
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 29人
url www.collplant.com
nasdaq_url https://www.nasdaq.com/symbol/clgn
adr_tso 149041
EBITDA EBITDA ー
終値(lastsale) 5.01
時価総額(marketcap) 746695.41
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 CLGNのテクニカル分析


 CLGNのニュース

   CollPlant to Supply rhCollagen to STEMCELL Technologies for Use in a Broad Range of Cell Culture Applications  2020/12/10 12:00:00 Benzinga
REHOVOT, Israel and VANCOUVER, BC , Dec. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN ), a regenerative medicine company, and STEMCELL Technologies, Canada's largest privately owned biotechnology company, which develops cell culture media, cell separation systems, instruments, and other reagents for life sciences research, today jointly announced they have entered into a product manufacturing and supply agreement. CollPlant will sell its proprietary recombinant human Type I collagen (rhCollagen), the world's first plant-based rhCollagen, to STEMCELL Technologies, which will incorporate CollPlant's product into cell culture media kits. The recently signed agreement follows the companies' established business relationship, which started in 2014 when STEMCELL began purchasing and incorporating CollPlant's rhCollagen into some of its cell culture expansion and differentiation media kits. To date, hundreds of companies, as well as research and academic institutes, have used these kits for research and development projects.
   CollPlant Receives Substantial First Order for its Vergenix™ Flowable Gel Product in Ukraine  2020/10/26 11:00:00 PR Newswire
REHOVOT, Israel, Oct. 26, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that it has received a substantial first order totaling hundreds of thousands of U.S. dollars for its Vergenix™ Flowable Gel (FG) product in Ukraine from…
   CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant  2020/09/21 11:00:00 PR Newswire
REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a…
   CollPlant Biotechnologies Signs Distribution Agreement for its Vergenix Flowable Gel Product in the Commonwealth of Independent States (CIS)  2020/09/14 11:00:00 PR Newswire
REHOVOT, Israel, Sept. 14, 2020 /PRNewswire/ -- CollPlant has already received first order amounting to hundreds of thousands of U.S. dollars Product distribution in six CIS countries expected to increase clinical use in new patient populations Recent peer-reviewed publication further…
   CollPlant Biotechnologies to Present at Science of Aging Virtual Symposium 2020 During Healthy Aging Month  2020/08/31 11:00:00 PR Newswire
REHOVOT, Israel, Aug. 31, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr. Nadav Orr, Vice President of R&D, will be presenting at the Science of Aging Virtual Symposium 2020. The event will be held virtually during…
   CollPlant to Supply rhCollagen to STEMCELL Technologies for Use in a Broad Range of Cell Culture Applications  2020/12/10 12:00:00 Benzinga
REHOVOT, Israel and VANCOUVER, BC , Dec. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN ), a regenerative medicine company, and STEMCELL Technologies, Canada's largest privately owned biotechnology company, which develops cell culture media, cell separation systems, instruments, and other reagents for life sciences research, today jointly announced they have entered into a product manufacturing and supply agreement. CollPlant will sell its proprietary recombinant human Type I collagen (rhCollagen), the world's first plant-based rhCollagen, to STEMCELL Technologies, which will incorporate CollPlant's product into cell culture media kits. The recently signed agreement follows the companies' established business relationship, which started in 2014 when STEMCELL began purchasing and incorporating CollPlant's rhCollagen into some of its cell culture expansion and differentiation media kits. To date, hundreds of companies, as well as research and academic institutes, have used these kits for research and development projects.
   CollPlant Receives Substantial First Order for its Vergenix™ Flowable Gel Product in Ukraine  2020/10/26 11:00:00 PR Newswire
REHOVOT, Israel, Oct. 26, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that it has received a substantial first order totaling hundreds of thousands of U.S. dollars for its Vergenix™ Flowable Gel (FG) product in Ukraine from…
   CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant  2020/09/21 11:00:00 PR Newswire
REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a…
   CollPlant Biotechnologies Signs Distribution Agreement for its Vergenix Flowable Gel Product in the Commonwealth of Independent States (CIS)  2020/09/14 11:00:00 PR Newswire
REHOVOT, Israel, Sept. 14, 2020 /PRNewswire/ -- CollPlant has already received first order amounting to hundreds of thousands of U.S. dollars Product distribution in six CIS countries expected to increase clinical use in new patient populations Recent peer-reviewed publication further…
   CollPlant Biotechnologies to Present at Science of Aging Virtual Symposium 2020 During Healthy Aging Month  2020/08/31 11:00:00 PR Newswire
REHOVOT, Israel, Aug. 31, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr. Nadav Orr, Vice President of R&D, will be presenting at the Science of Aging Virtual Symposium 2020. The event will be held virtually during…
   CollPlant Receives Substantial First Order for its Vergenix™ Flowable Gel Product in Ukraine  2020/10/26 11:00:00 PR Newswire
REHOVOT, Israel, Oct. 26, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that it has received a substantial first order totaling hundreds of thousands of U.S. dollars for its Vergenix™ Flowable Gel (FG) product in Ukraine from…
   CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant  2020/09/21 11:00:00 PR Newswire
REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a…
   CollPlant Biotechnologies Signs Distribution Agreement for its Vergenix Flowable Gel Product in the Commonwealth of Independent States (CIS)  2020/09/14 11:00:00 PR Newswire
REHOVOT, Israel, Sept. 14, 2020 /PRNewswire/ -- CollPlant has already received first order amounting to hundreds of thousands of U.S. dollars Product distribution in six CIS countries expected to increase clinical use in new patient populations Recent peer-reviewed publication further…
   CollPlant Biotechnologies to Present at Science of Aging Virtual Symposium 2020 During Healthy Aging Month  2020/08/31 11:00:00 PR Newswire
REHOVOT, Israel, Aug. 31, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr. Nadav Orr, Vice President of R&D, will be presenting at the Science of Aging Virtual Symposium 2020. The event will be held virtually during…
   Is CollPlant Holdings Ltd. Sponsored (CLGN) Outperforming Other Medical Stocks This Year?  2020/06/03 15:30:17 Zacks Investment Research
Is (CLGN) Outperforming Other Medical Stocks This Year?

 関連キーワード  (― 米国株 コルプラント・ホ―ルディングス CLGN CollPlant Holdings Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)